Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial-Reference-Cited by-同舟云学术

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Published:2015-05 Issue:9980 Volume:385 Page:1873-1883
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hillmen Peter,Robak Tadeusz,Janssens Ann,Babu K Govind,Kloczko Janusz,Grosicki Sebastian,Doubek Michael,Panagiotidis Panagiotis,Kimby Eva,Schuh Anna,Pettitt Andrew R,Boyd Thomas,Montillo Marco,Gupta Ira V,Wright Oliver,Dixon Iestyn,Carey Jodi L,Chang Chai-Ni,Lisby Steen,McKeown Astrid,Offner Fritz

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. Chronic lymphocytic leukemia in less fit patients: “slow-go”;Del Giudice;Leuk Lymphoma,2011

2. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia;Foon;Blood,2012

3. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia;Forconi;Hematol Oncol,2008

4. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group;Fischer;J Clin Oncol,2012

5. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia;Knauf;J Clin Oncol,2009

Cited by 301 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-09

2. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. A decade of chronic lymphocytic leukaemia therapy in Germany: Real‐world treatment patterns and outcomes (2010–2022);eJHaem;2024-04

4. Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia;OncoTargets and Therapy;2024-03

5. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US;The Oncologist;2024-01-27